08:00 , Jan 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Neuropeptide Y receptor Y2 (NPY2R); peptide tyrosine-tyrosine (PYY) Mouse studies suggest PYY delivered as an...
07:00 , Apr 14, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Obesity Neuropeptide Y receptor Y2 (NPY2R); NPY4R Studies in mice suggest that a lipidated peptide agonist...
07:00 , Aug 12, 2010 |  BC Innovations  |  Targets & Mechanisms

The GPCR-cancer connection

Researchers from Roche's Genentech Inc.unit have identified a host of somatic mutations and gene copy number alterations across human cancers that represent potential targets for the disease.1 Nineteen of the 112 candidate cancer genes identified...
08:00 , Jan 29, 2009 |  BC Innovations  |  Cover Story

Wising up to NPYs

In the mid-1990s, neuropeptide Y was thought to be a promising obesity target based on its activity in the CNS as a potent feeding stimulator. However, the approach didn't succeed and only one company is...